Dose Finding Study With CYT003-QbG10 in Patients With House Dust Mite Allergy
Launched by CYTOS BIOTECHNOLOGY AG · Dec 1, 2008
Trial Information
Current as of June 05, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Perennial allergic rhinoconjunctivitis due to clinically relevant allergy towards house dust mite allergens
- • Further criteria as defined in the study protocol
- Exclusion Criteria:
- • Clinically manifested seasonal allergy/-ies which is/are expected to interfere with the patient's study treatment schedule and/or assessments
- • Clinically relevant perennial allergy/-ies other than house dust mites allergy
- • Contraindication to any study test or procedure
- • Further criteria as defined in the study protocol
About Cytos Biotechnology Ag
Cytos Biotechnology AG is a biopharmaceutical company focused on the development of innovative therapeutic solutions for unmet medical needs. With a strong emphasis on harnessing the power of the immune system, Cytos is dedicated to advancing its proprietary technologies in the fields of vaccine development, immunotherapy, and targeted biologics. The company’s robust pipeline reflects its commitment to scientific excellence and patient-centric approaches, positioning it as a key player in the biotechnology landscape. Through strategic collaborations and a focus on clinical research, Cytos aims to bring transformative treatments to market, enhancing the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Paide, Tartu, Tallin, Rakvere, , Estonia
Fulda, Dresden, Ulm, Rodgau, Kassel, Eisenach, , Germany
Wiesbaden, Frankfurt/M, Leipzig, Jena, Hamburg, Dulmen, , Germany
N. Faliro, Hiraklion, Athens, , Greece
Riga, Rezekne, , Latvia
Vilnius, Kaunas, Klaipeda, , Lithuania
Galati, Cluj Napoca, Bahia Mare, Brasov, Piesti, , Romania
Targu Mures, Bukarest, Craiova, Iasi, , Romania
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials